

COMMONWEALTH OF VIRGINIA DEPARTMENT OF MEDICAL ASSISTANCE SERVICES Service Authorization (SA) Form

GLP-1 RECEPTOR AGONISTS FOR OBSTRUCTIVE SLEEP APNEA

If the following information is not complete, correct, or legible, the SA process can be delayed.

Please use one form per member.

MEMBER INFORMATION			
Last Name:	First Name:		
Medicaid ID Number:	Date of Birth:		
	Weight in Kilograms:		
PRESCRIBER INFORMATION			
Last Name:	First Name:		
NPI Number:			
Phone Number:	Fax Number:		
DRUG INFORMATION			
•	for renewal requests, proceed to <u>Length of Authorization</u> . If approved, 5 months. Renewal authorizations are granted for 12 months.		
Drug Name/Form:			
Strength:			
Dosing Frequency:			
Length of Therapy:			
Ouantity per Day:			

- FDA indicated medications only
- Must be prescribed by an otolaryngologist (ENT), neurologist, pulmonologist, or sleep apnea specialist for the member to receive authorization

(Form continued on next page.)

Virginia DMAS SA Form: GLP-1 Receptor Agonists for Obstructive Sleep Apnea

Member's Last Name: Member's First Name:		
DIAGNOSIS AND MEDICAL INFORMATION		
1.	Is the member is 18 years of age or older? AND Yes No	
2.	Is the requesting provider managing the member's obstructive sleep apnea? AND Yes No	
3.	Does the member have a diagnosis of moderate to severe obstructive sleep apnea (OSA), defined by an apnea-hypopnea index ≥ 15 events/hour and confirmed by polysomnography? AND Yes No	
 Is the member is currently on or has the member tried, failed, or been unable to tolerate continuous positive airway pressure therapy (CPAP) (an adequate trial is defined as CPAP use for ≥ 4 hours per ni on ≥ 70% of nights for two or more months)? AND 		
	☐ Yes ☐ No	
	If unable to tolerate CPAP therapy, please explain the intolerance below:	
5.	Does the member have a body mass index (BMI) of $\geq 30 \text{kg/m}^2$? AND	
	☐ Yes ☐ No	
6.	Has the member participated in a weight loss treatment plan (e.g. nutritional counseling, an exercise regimen, and calorie restricted/fat restricted diet) in the past 6 months and will they continue to follow this treatment plan while taking an anti-obesity medication for obstructive sleep apnea? AND	
	☐ Yes ☐ No	
7.	Does the member does have craniofacial abnormalities that may affect breathing? AND	
	☐ Yes ☐ No	
8.	Does the member have a diagnosis of central or mixed sleep apnea or Cheyne-Stokes respiration? AND	
	☐ Yes ☐ No	
9.	Is the member using any other GLP-1 product? AND	
	☐ Yes ☐ No	
10	. Does the member have pancreatitis, acute suicidal behavior/ideation, or gastroparesis, is the member using prokinetic drugs (e.g., metoclopramide), or does the member have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 syndrome?	
	☐ Yes ☐ No	
(Fc	orm continued on next page.)	

Virginia DMAS SA Form: GLP-1 Receptor Agonists for Obstructive Sleep Apnea

Member's Last Name:	Member's First Name:	
ATTESTATION AND DOCUMENTATION		
Submission of polysomnography conducted within	the last 12 months	
Submission of weight loss treatment plan within th	e past 6 months	
LENGTH OF AUTHORIZATION		
Renewal requests (see additional requirements below	v):	
1. Does the member continues to meet the criteria? AND		
Yes No		
2. Is the member being treated with a maintenance dosage of the requested drug? AND		
Yes No		
3. Is documentation attached verifying that the member has experienced improvement in OSA symptoms?		
Yes No		
Attachments		
Prescriber Signature (Required)	Date	
By signature, the physician confirms the above informa	ation is accurate and verifiable by member records.	
Please include ALL requested information; incomplete Submission of documentation does NOT guarantee cov Services.		

Fax this form to 1-866-940-7328

Pharmacy PA Call Center 1-800-310-6826

Confidentiality Notice: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender (via return fax) immediately and arrange for the return or destruction of these documents. Distribution, reproduction or any other use of this transmission by any party other than the intended recipient is strictly prohibited.